Next generation exon skipping therapies for Duchenne Muscular Dystrophy (DMD) represent a promising area of research aimed at addressing the underlying genetic mutations that...
Insmed is getting ready to use its ground-breaking gene therapy, INS1201, to combat Duchenne muscular dystrophy. Insmed intends to start Phase I clinical trials...
We are happy to present the winners of the American Neuromuscular Foundation's (ANF) 2024 Investigator Grant Award. Liubov Gushchina, PhD, received the prize for...
The FDA has granted IPS HEART Orphan Drug Designation (ODD) for GIVI-MPCs because of its exceptional capacity to produce new muscle with full length...